https://azd2281inhibitor.com/t....he-effects-associate
Until recently just first stages of ATTRv-PN (polyneuropathy) had access to disease-modifying therapy (DMT), whereas there was clearly no certain treatment for ATTRv-CM (cardiomyopathy). This analysis updates our knowledge about outcomes of three stage 3 medical trials, specialist's consensus for very early diagnosis and emerging biomarkers. Two phase 3 studies using RNAi and antisense oligonucleotides (ASO) had been successful. Major endpoints were progression of neuropathic score mNIS
Like
Comment
Share
